A Phase 3, Double-blind, Parallel-group Study to Evaluate the Efficacy and Safety of Tezacaftor in Combination With Ivacaftor in Subjects Aged 6 Through 11 Years With Cystic Fibrosis, Homozygous or Heterozygous for the F508del-CFTR Mutation
Phase of Trial: Phase III
Latest Information Update: 05 Feb 2019
At a glance
- Drugs Ivacaftor/tezacaftor (Primary) ; Ivacaftor
- Indications Cystic fibrosis
- Focus Registrational; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 25 Jan 2019 Status changed from active, no longer recruiting to completed.
- 26 Apr 2018 According to Vertex Pharmaceuticals media release, data are expected in the second half of 2018.
- 26 Apr 2018 Status changed from not stated to active, no longer recruiting, according to Vertex Pharmaceuticals media release.